Sanofi | GenomeWeb


Sanofi recruits one of AstraZeneca's top scientists to bolster its biotech presence, Reuters reports.

The collaboration will focus on identifying new signaling pathways and targets involved in coronary artery disease.

The study used a modified version of Myriad RBM's DiscoveryMAP immunoassay panel to measure levels of 237 proteins in blood samples from 8,401 patients.

The pharma firm joins Pfizer Canada and AstraZeneca in the National Access Project, which tests tumors for mutations to match patients with potential therapies.

The two methods could shorten the detection time by eliminating the need to amplify the virus with in vitro cell culture.

The data show that RG-012 can enhance the effect of Sanofi's kidney protectant ramipril and suggest the microRNA drug might have use in other chronic kidney diseases.

Title: Treatment of Cancer by Inhibition of IGFBPs and Clusterin
Patent Number: 8,835,401
Filed: May 29, 2013

NEW YORK (GenomeWeb) — Illumina has partnered with AstraZeneca, Janssen Biotech, and Sanofi to develop a universal next-generation sequencing-based oncology test system for multi-analyte companion diagnostics, the company said today.

Can drugmakers be held liable for failing to aggressively warn consumers that patients with certain genetic markers will not respond or will have limited response to their drugs beyond just mentioning this information in drug labeling?


In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.